Genocea lands a massive $35M Series B round

Genocea Biosciences Inc., a Cambridge biotech working on novel vaccines for diseases like herpes and malaria, has taken a huge second funding round, pulling in $35 million in Series B financing and adding Johnson & Johnson Development Corp. to its roster of backers.

The company also took the opportunity to name biotech veteran Seth Hetherington as its chief medical officer. As part of the financing, Stephen J. Hoffman, managing director at Skyline Ventures, another new backer, has joined the Genocea board.